Fuso Pharmaceutical IndustriesFuso Pharmaceutical Industries,Ltd.4538東証プライム医薬品FY ending Mar 2026, non-consolidated, J-GAAP
Out of every ¥100 of sales, about ¥4 is left as operating profit. Revenue changed +2.9% from the prior year, operating profit -36.1%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 3.0% | 0.72× | 2.1% | 1.81× | 3.9% |
| 2023 | 3.1% | 0.72× | 2.3% | 1.82× | 4.1% |
| 2024 | 2.5% | 0.75× | 1.9% | 1.88× | 3.5% |
| 2025 | — | —× | -4.2% | —× | — |
| 2026 | 3.2% | 0.72× | 2.3% | 2.37× | 5.5% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 49,632 | 51,015 | 55,407 | 60,563 | 62,307 |
| Cost of revenue | 36,235 | 37,275 | 41,568 | 44,030 | 46,312 |
| Gross profit | 13,397 | 13,740 | 13,838 | 16,532 | 15,995 |
| SG&A | 11,473 | 11,533 | 11,874 | 12,401 | 13,355 |
| Operating income | 1,924 | 2,206 | 1,964 | 4,131 | 2,639 |
| Pretax income | 1,911 | 2,205 | 1,767 | -4,970 | 2,438 |
| Income tax | 427 | 599 | 389 | -1,682 | 426 |
| Net income attributable to owners | 1,483 | 1,605 | 1,377 | -3,288 | 2,011 |
| Operating margin | 3.9% | 4.3% | 3.5% | 6.8% | 4.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥7.35B | ¥8.01B | ¥5.12B | ¥6.26B | ¥4.85B |
| Total assets | ¥69.3B | ¥72.5B | ¥75.8B | ¥81.7B | ¥90.3B |
| Net assets | ¥34.5B | ¥35.6B | ¥36.7B | ¥33B | ¥35.1B |
| Share capital | ¥10.8B | ¥10.8B | ¥10.8B | ¥10.8B | ¥10.8B |
| Trade receivables | — | — | — | ¥26.5B | ¥26.9B |
| Property, plant and equipment | ¥23.8B | ¥23.8B | ¥24.4B | ¥23.1B | ¥22.2B |
| Intangible assets excluding goodwill | ¥453M | ¥329M | ¥600M | ¥1.51B | ¥1.35B |
| Investment securities | ¥3.09B | ¥3.02B | ¥3.92B | ¥4.38B | ¥5.33B |
| Current assets | ¥39.8B | ¥43.2B | ¥44.9B | ¥48.3B | ¥57.3B |
| Current liabilities | ¥26.4B | ¥28.5B | ¥29.6B | ¥44.1B | ¥51.7B |
| Short-term borrowings | ¥2.35B | ¥2.35B | ¥2.35B | ¥18B | ¥26B |
| Long-term borrowings | ¥5.76B | ¥5.75B | ¥7.02B | ¥2.46B | ¥1.86B |
| Total liabilities | ¥34.8B | ¥36.8B | ¥39.1B | ¥48.7B | ¥55.3B |
| Equity attributable to owners of parent | ¥38.3B | ¥39.4B | ¥39.7B | ¥35.7B | ¥37B |
| Retained earnings | ¥14.7B | ¥15.8B | ¥16.5B | ¥12.6B | ¥13.9B |
| Treasury stock | -¥2.17B | -¥2.17B | -¥2.59B | -¥2.59B | -¥2.6B |
EDINET (FSA Japan)
有価証券報告書－第103期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第102期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第101期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第100期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第99期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第98期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 50 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.